State of New Jersey Common Pension Fund D Purchases Shares of 14,598 CG Oncology, Inc. $CGON

State of New Jersey Common Pension Fund D acquired a new position in shares of CG Oncology, Inc. (NASDAQ:CGON) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,598 shares of the company’s stock, valued at approximately $606,000.

A number of other large investors have also recently made changes to their positions in CGON. Whittier Trust Co. of Nevada Inc. acquired a new position in shares of CG Oncology during the fourth quarter valued at about $27,000. Strengthening Families & Communities LLC acquired a new stake in shares of CG Oncology in the 3rd quarter worth about $40,000. Comerica Bank raised its holdings in shares of CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after acquiring an additional 515 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in CG Oncology by 33.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after acquiring an additional 972 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in CG Oncology by 159.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock valued at $182,000 after purchasing an additional 4,288 shares during the last quarter. 26.56% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CGON has been the subject of a number of recent research reports. Royal Bank Of Canada boosted their price objective on CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a report on Monday. JPMorgan Chase & Co. lifted their target price on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday. Wall Street Zen downgraded CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Truist Financial reissued a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of CG Oncology in a research report on Monday. Finally, Wedbush raised their price objective on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $81.27.

Key Stories Impacting CG Oncology

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: JPMorgan raised its price target to $96 and kept an overweight rating, implying substantial upside from current levels.
• Positive Sentiment: Royal Bank of Canada lifted its target to $81 with an outperform rating, while Truist and Wedbush also increased targets, reinforcing bullish analyst sentiment.
• Positive Sentiment: CG Oncology said its presence at the AUA Annual Meeting highlights its commitment to NMIBC, with first results from the CORE-008 Cohort CX Phase 2 trial set to be presented, keeping attention on its pipeline and clinical progress. Article Title
• Neutral Sentiment: Analysts have been boosting forecasts following Q1 earnings, suggesting expectations are improving, but the latest quarter was described as mixed. Article Title
• Negative Sentiment: The Q1 report showed a wider loss than expected, and another report noted that CG Oncology still has a cash runway through 2029, highlighting ongoing burn and lack of near-term profitability. Article Title

CG Oncology Stock Down 0.4%

Shares of NASDAQ CGON opened at $69.32 on Tuesday. The company has a market capitalization of $6.10 billion, a PE ratio of -29.75 and a beta of 0.41. The stock’s 50 day moving average price is $66.18 and its 200-day moving average price is $53.24. CG Oncology, Inc. has a twelve month low of $23.32 and a twelve month high of $73.56.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. As a group, research analysts expect that CG Oncology, Inc. will post -2.56 EPS for the current fiscal year.

Insider Transactions at CG Oncology

In other CG Oncology news, Director James Mulay sold 15,600 shares of the company’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $73.01, for a total value of $1,138,956.00. Following the completion of the transaction, the director owned 15,600 shares in the company, valued at $1,138,956. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.80% of the stock is owned by company insiders.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.